A Los Angeles-based company, catering to human well-being, came out with news that rocked small cap markets Thursday.
Endonovo Therapeutics, Inc. (OTC: ENDV), makers of the non-invasive Electroceutical™ System device, SofPulse®, declared progress in the process of commercializing the device.
The company his initiated additional sales and marketing strategies to ensure future growth, including hiring an independent sales force; and following through on an agreement recently announced with U.S. Authentic Trading Company to handle distribution throughout hospitals in China.
Endonovo says it anticipates definitive agreements to be executed in the first quarter of 2019.
CEO Alan Collier says "The Company has received numerous calls and emails from medical professionals and patients alike, detailing the beneficial results stemming from the use of SofPulse®. We believe this performance further reinforces and validates the commercial maturity of SofPulse® while demonstrating the capacity to address medical issues without patients being prescribed and dependent on opioids."
SofPulse uses pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds.
ENDV shares gained 10.5% to 2.405 cents late Thursday, on volume of 1.7 million shares.
